Industry observers note that the U.S. IPO market has rebounded, but the recovery remains uneven. Companies seeking to go public face investors focused on durable revenue, profitability and valuation, while uncertainty has prompted some issuers to postpone their offerings.
In a recent development, mike Bellin, a partner and U.S. IPO services leader at PricewaterhouseCoopers, sees a market that remains open to companies with the right scale, financial metrics and preparation.
In a recent development, in a recent conversation with Crunchbase News, Bellin discussed the slowdown in IPO momentum, how public investors are evaluating AI companies, biotech’s resurgence and why SPACs are attracting renewed interest. He also outlined what could set the stage for a stronger start to 2027.
This interview has been edited for length and clarity.
Crunchbase News: How healthy is the IPO market right now?
According to recent reports, bellin: A good IPO year in the U.S. is anywhere from 125 to 175 traditional IPOs, and year to date we’ve seen just south of 90 or so.
The breadth of the market indicates me that it’s been a healthy market. We’ve seen industrial products come back to market. We’ve seen tech, consumer markets, energy, utilities and some financial services come back to market.
Industry observers note that for the majority of the first three quarters of the year, it was a pretty strong and broad IPO market. But the momentum has halted significantly since September and October.
Is the market in trouble? I would say no. It’s very selective. It’s not shut. Quality issuers with readiness, the right story, the right metrics can still get their deals done.
What has contributed to the slowdown?
According to recent reports, bellin: The macro environment in general was the big mover: rates, inflation, geopolitical concerns. Just that uncertainty was a big factor.
Recent findings suggest that one of the massive factors that I’ve seen is valuation. Some fairly aggressive valuations were being asked for in certain transactions, certain offerings, and I think the market — with all those uncertainties that I mentioned — was looking at those valuations and thinking it was maybe a bit rich.
I believe many issuers decided to hit pause and wait for another window to open.
What are public market investors looking for?
It has been revealed that bellin: What investors are really looking for is durable revenue — revenue that’s backed up by strong customers, diverse customers and a growing revenue base. I think it’s that revenue reliability where there is a significant backlog of demand for the product, the services of the IPO issuer. That’s always a strong sign.
According to recent reports, the other item is leverage. For companies with significant leverage in a rising-rate environment, the questions are: Can they take on fresh leverage that creates profitable value opportunities going forward? Can they refinance existing leverage given rates are higher?
Making sure that you’re going into the capital markets with a reasonable leverage ratio, or explaining through your equity story how you’re getting a return on the capital that you have invested from a debt perspective, makes a significant difference.
Is the market open to a broad range of venture-backed startups, or primarily larger companies?
Bellin: Scale matters. Companies that have that scale, whether it’s from a revenue perspective or an asset-based perspective, depending on the sector, make a substantial difference. Those are the types of companies that can almost dictate the window that they’re going to go out in and do well.
Some of the smaller companies, the midmarket companies, smaller-cap companies — again, outside of life science and biotechs — they’ve been a little bit challenged.
If you’re growing at the right rate, you’re showing the right metrics, the IPO market is fully available to those types of companies. But if you’re still on the lower-scale side of the house, your opportunities may be limited to hit the market.
Will enthusiasm for AI companies carry into public markets, or will investors be more skeptical?
Bellin: I think investors aren’t skeptical of AI; they’re skeptical of spend without visibility — visibility to future earnings, visibility to that revenue durability that I mentioned.
The market is separating AI companies with visible demand from the ones with only a narrative out there, and I think that demand, that growth, the backlog is key.
The other factor we’re seeing in today’s market again comes down to cash generation and profitability. If you’re not profitable, when will that profitable period come? Profitability comes in many different measures. Could be GAAP income, could be EBITDA income, but also cash flows and free cash flows and levered free cash flows that are available to the organization.
In a recent development, we haven’t seen a period like this of development, of growth, ever before. It’s exciting, but I do think the market will discern between those companies that are public-company worthy and those that are not.
What does the uneven performance of newly public companies signal?
Bellin: It signals selectivity. There have been some really significant winners in the IPO market, and others that, post-issuance, haven’t traded as well as many expected.
Sources indicate that many of the companies that are coming to market have to be very thoughtful on the valuation and what you’re going to go price at. If you’re trying to be too aggressive on pricing, you may trade down post-IPO, which is going to impact those metrics.
Overall, we’re seeing strong candidates come to market. I do think companies are coming to market better prepared now than ever, given this volatility.
What is driving biotech’s resurgence?
Recent findings suggest that bellin: The M&A market for many of these companies is very strong today. As some of the larger health company names lose the patents to some of the profitable drugs, they’re looking at that next generation of development and where there could be value.
Many of these biotechs were purchased by large pharma companies even before coming to the public markets. That competition for these assets and companies is creating a nice horse trade between an IPO opportunity with a lot of upside and an M&A exit with more certainty day one.
I think M&A is the engine behind the IPO market’s resurgence for these companies.
According to recent reports, in the IPO markets, many of these assets have traded very well, and that’s where the momentum and that flywheel effect in the IPO market is very vital. We’ve seen that flywheel and that momentum in biotech. We haven’t seen it in the rest of the market in the last couple of months.
Why are SPACs attracting renewed interest?
Bellin: With market volatility, we’re seeing more conversations around SPACs. Because SPACs set valuation certainty on day one, a organization looking to exit via SPAC understands the potential cash that may come their way. It’s not certain, of course, given redemptions, etc.
Recent findings suggest that another factor driving a healthy SPAC market may be these serial SPAC issuers. They understand the SPAC product. They understand what makes a good de-SPAC candidate, and they know whether the target organization can be ready, show growth and hit the milestones that may be discussed in the offering document.
According to recent reports, the market is healthier and more mature today than in the past. That noted, we’re still seeing many SPACs continue to look for a target, given the massive SPAC inventory available to target companies.
It has been revealed that bellin: Hundreds of companies are in the pipeline, and they’re ready to go when the market is. Much of the remainder of ’26, and the start of 2027, depends on market momentum.
I’m an eternal optimist. There’s a lot of demand on the buy side; there’s still significant capital available to the right companies. So if we can create that momentum here in the remaining months of 2026, I think we’re going to see a strong start to 2027.
According to recent reports, the AI ecosystem that we’ve been talking about is healthy. Demand for energy is always significant, and the right energy companies are coming to market. Consumer and industrial products — those are coming back.
Private equity has been very active in ’26, and I’d expect them to continue that activity in 2027.
I think we’re in for a strong year, but it will remain selective.
Stay up to date with recent funding rounds, acquisitions, and more with the Crunchbase Daily.
London-based startup investor Plural, with a portfolio mix of energy, compute, defense, robotics, health and software, says it has closed on its...
Discover and act on private market opportunities with predictive organization intelligence.
